Shenzhen Chipscreen Biosciences Co Ltd
SSE:688321

Watchlist Manager
Shenzhen Chipscreen Biosciences Co Ltd Logo
Shenzhen Chipscreen Biosciences Co Ltd
SSE:688321
Watchlist
Price: 19.4 CNY -0.82%
Market Cap: 7.9B CNY
Have any thoughts about
Shenzhen Chipscreen Biosciences Co Ltd?
Write Note

Shenzhen Chipscreen Biosciences Co Ltd
Accrued Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Shenzhen Chipscreen Biosciences Co Ltd
Accrued Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accrued Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Shenzhen Chipscreen Biosciences Co Ltd
SSE:688321
Accrued Liabilities
ÂĄ56.8m
CAGR 3-Years
30%
CAGR 5-Years
50%
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Accrued Liabilities
ÂĄ2B
CAGR 3-Years
2%
CAGR 5-Years
14%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Accrued Liabilities
ÂĄ620.1m
CAGR 3-Years
74%
CAGR 5-Years
53%
CAGR 10-Years
31%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Accrued Liabilities
ÂĄ128.5m
CAGR 3-Years
456%
CAGR 5-Years
130%
CAGR 10-Years
63%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Accrued Liabilities
ÂĄ1.5B
CAGR 3-Years
74%
CAGR 5-Years
54%
CAGR 10-Years
46%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Accrued Liabilities
ÂĄ146m
CAGR 3-Years
-11%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Shenzhen Chipscreen Biosciences Co Ltd
Glance View

Market Cap
7.9B CNY
Industry
Pharmaceuticals

In the bustling city of Shenzhen, often hailed as China's Silicon Valley, Shenzhen Chipscreen Biosciences Co Ltd stands as a testament to innovation in the biopharmaceutical landscape. Founded in 2001, the company embarked on a journey to bridge the gap between cutting-edge bioscience and market needs, focusing on research, development, and commercialization of novel drugs. Chipscreen’s core strength lies in its proprietary chemical genomics-based discovery and development platform, which has carved out a niche in identifying molecular targets and mining drug candidates with high therapeutic potential. The company seamlessly integrates advanced technologies with biotech prowess to design and develop small molecule drugs that address unmet clinical needs, primarily focusing on oncology, autoimmune diseases, and metabolic disorders. The financial engine of Chipscreen Biosciences hums through a well-orchestrated portfolio strategy. By progressing drug candidates through various stages of clinical trials, the company has not only diversified its offerings but also strategically positioned itself in lucrative therapeutic markets. Its revenue model capitalizes on successful product commercialization, primarily through sales of its marketed drugs and royalties from licensing agreements with strategic partners. This collaborative approach enables Chipscreen to maximize its product reach while sharing developmental risks. As the company's innovative therapies gain traction in domestic and global markets, Chipscreen continues its commitment to reinvest in research and development, crafting a sustainable cycle of growth fueled by scientific advancement and strategic acumen.

Intrinsic Value
12.34 CNY
Overvaluation 36%
Intrinsic Value
Price

See Also

What is Shenzhen Chipscreen Biosciences Co Ltd's Accrued Liabilities?
Accrued Liabilities
56.8m CNY

Based on the financial report for Sep 30, 2024, Shenzhen Chipscreen Biosciences Co Ltd's Accrued Liabilities amounts to 56.8m CNY.

What is Shenzhen Chipscreen Biosciences Co Ltd's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 5Y
50%

Over the last year, the Accrued Liabilities growth was 43%. The average annual Accrued Liabilities growth rates for Shenzhen Chipscreen Biosciences Co Ltd have been 30% over the past three years , 50% over the past five years .

Back to Top